TendoNova’s Ocelot™ system is a novel way to treat chronic tendon pain. It consists of a hand-held reusable unit, a single-use disposable component, and real-time feedback for the physician to assess procedure effectiveness. It has been designed to provide cost-effective treatment that can be performed in a clinician’s office. The resulting system improves the patient experience, reduces cost/procedure, with the benefit of improved outcomesPatients are caught in the gap between conservative treatment of chronic tendon pain and variable outcomes.

TendoNova’s Ocelot™ system is a novel, financially-efficient, clinically-effective tool that consists of a hand-held reusable unit, a disposable component, and real-time data capture for the physician to see treatment effectiveness. The result improves the patient experience, reduces cost/procedure, with the benefit of improved outcomes.

Every year in the US alone, at least 8 million people are caught in the gap between conserv...
TendoNova’s Ocelot™ system is a novel way to treat chronic tendon pain. It consists of a hand-held reusable unit, a single-use disposable component, and real-time feedback for the physician to assess procedure effectiveness. It has been designed to provide cost-effective treatment that can be performed in a clinician’s office. The resulting system improves the patient experience, reduces cost/procedure, with the benefit of improved outcomesPatients are caught in the gap between conservative treatment of chronic tendon pain and variable outcomes.

TendoNova’s Ocelot™ system is a novel, financially-efficient, clinically-effective tool that consists of a hand-held reusable unit, a disposable component, and real-time data capture for the physician to see treatment effectiveness. The result improves the patient experience, reduces cost/procedure, with the benefit of improved outcomes.

Every year in the US alone, at least 8 million people are caught in the gap between conservative treatment of tendon pain and open surgery. There is presently no cost effective, office based,treatment for tendinopathy and many people forgo treatment due to cost constraints or choose ineffective alternatives. In addition, surgical treatments require extensive experience and there is a need for surgical feedback systems to reduce learning times.

Target market is smaller-scale physician practices where tendon repair procedures can be completed without the expense and risk of a surgical setting. The target users will be physiatrists, rehabilitation and sports medicine physicians, podiatrists. Key opinion leaders will be from successful clinics and academic centers. The US market is estimated at $1.2 billion and the European market is forecast at €1.5 billion.

This is a classic example of a razor-and-blade business model with the addition of a big-data component. The short-term business model is driven by the single-use, high-margin component of the system. At less than ½ of existing reimbursement rates, we also provide an attractive margin for physicians’ practices, with will drive adoption. Longer-term value will see additional contribution from leverage of data gathered by the system.

Four competition categories each have distinct shortcomings: medication and physical therapy, needle tenotomy, injected therapeutics, and percutaneous technologies. Technologies are offered from Hydrocision (TenJet system) and Tenex Health (TX system) but suffer from system reliability
More information

Employees

mark samuels
Admin
mark samuels CEO Medical technology leader with 30+ years of experience in bringing new technologies into clinical practice. ATA exit - OBMedical